Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 3/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21305163 | 0.80 | PI4KA (0.38) | TNKSTNKS2SCN10APKMHTR1D | |
| SCHEMBL26997375 | 0.80 | TNKS (0.35) | TNKSTNKS2SCN10ATSHRAMY1A | |
| SCHEMBL29297544 | 0.77 | — | — | |
| SCHEMBL17811228 | 0.73 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL18233734 | 0.72 | ALDH1A1 (0.33) | LMNAKDM4EALDH1A1KMT2A | |
| SCHEMBL21672761 | 0.72 | GRIA1 (0.33) | KIF11 | |
| SCHEMBL29297345 | 0.70 | — | — | |
| SCHEMBL24657617 | 0.66 | TP53 (0.33) | KDM4EALDH1A1KMT2A | |
| SCHEMBL21669986 | 0.65 | TSHR (0.33) | SCN10ATSHRHTR1DLMNATYR | |
| SCHEMBL21305156 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228490-A1 | HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | TNKS 1799/4885TNKS2 2216/4885SCN10A 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.